Want to see IN:BROOKS full AI Analyst Report?

Brooks Laboratories Limited (BROOKS) Price & Analysis

2 Followers

BROOKS Stock Chart & Stats

₹62.75

-₹1.20(-1.88%)

At close: Jul 28 4:00 PM EDT

₹62.75

-₹1.20(-1.88%)

Day’s Range― - ―

52-Week Range₹36.50 - ₹162.80

Previous CloseN/A

Volume7.49K

Average Volume (3M)2.20K

Market Cap

₹1.81B

Enterprise Value₹1.11K

Total Cash (Recent Filing)₹75.49M

Total Debt (Recent Filing)₹85.17M

Price to Earnings (P/E)14.0

Beta1.60

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)8.35

Shares Outstanding29,457,249

10 Day Avg. Volume1,280

30 Day Avg. Volume2,199

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.89

Price to Sales (P/S)1.27

P/FCF Ratio21.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Profitability TurnaroundThe return to strong profitability improves internal funding capacity and indicates that the business can generate earnings after several loss-making years, although consistency must still be demonstrated.

Conservative LeverageVery low leverage reduces interest and refinancing pressure, preserves financial flexibility, and gives Brooks greater capacity to withstand operating volatility or fund future business requirements.

Cash Flow RecoveryThe shift to positive operating and free cash flow is an important improvement in financial resilience, suggesting that operations are beginning to support investment and liquidity needs more effectively.

Bears Say

Revenue ContractionA sharp top-line decline weakens operating scale and raises questions about product demand, customer retention, or competitive position, making the recent earnings recovery harder to assess as durable.

Weak Cash ConversionWeak conversion of accounting profit into operating cash can indicate working-capital demands or earnings quality concerns, limiting the company’s ability to reinvest, reduce risk, or return capital consistently.

Earnings VolatilityThe history of losses and unstable margins reduces confidence that current profitability represents a sustainable baseline, leaving future earnings exposed to operational or product-mix fluctuations.

Brooks Laboratories Limited News

Brooks Laboratories Announces Strategic Merger of Joint Venture

Brooks Laboratories Limited ( ($IN:BROOKS) ) has shared an announcement. Brooks Laboratories Limited has announced a merger by...

11M ago

BROOKS FAQ

What was Brooks Laboratories Limited’s price range in the past 12 months?

Brooks Laboratories Limited lowest stock price was ₹36.50 and its highest was ₹162.80 in the past 12 months.

What is Brooks Laboratories Limited’s market cap?

Brooks Laboratories Limited’s market cap is ₹1.81B.

When is Brooks Laboratories Limited’s upcoming earnings report date?

Brooks Laboratories Limited’s upcoming earnings report date is Nov 06, 2026 which is in 71 days.

How were Brooks Laboratories Limited’s earnings last quarter?

Brooks Laboratories Limited released its earnings results on Aug 13, 2026. The company reported -₹0.607 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Brooks Laboratories Limited overvalued?

According to Wall Street analysts Brooks Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brooks Laboratories Limited pay dividends?

Brooks Laboratories Limited does not currently pay dividends.

What is Brooks Laboratories Limited’s EPS estimate?

Brooks Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Brooks Laboratories Limited have?

Brooks Laboratories Limited has 29,457,249 shares outstanding.

What happened to Brooks Laboratories Limited’s price movement after its last earnings report?

Brooks Laboratories Limited reported an EPS of -₹0.607 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5%.

Which hedge fund is a major shareholder of Brooks Laboratories Limited?

Currently, no hedge funds are holding shares in IN:BROOKS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Brooks Laboratories Limited

Brooks Laboratories Limited is a pharmaceutical enterprise engaged in the contractual manufacturing and distribution of medicinal products. The company serves both the Indian domestic market and international clients. Its comprehensive product portfolio includes carbapenem medications, various tablets, dry syrups, both liquid and powdered injectable solutions, and specialized eye and ear drops. Brooks Laboratories Limited was established in 2002 and is headquartered in Mumbai, India.